Diligence memo · auto-generated · as of July 2, 2026

Enrich Biosystems Inc.

Enrich Biosystems Inc. looks fair against its niche peers and is active on financing cadence.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

Enrich Biosystems Inc. operates in Biotechnology, based in BRANFORD.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Enrich Biosystems Inc. has raised $8.2M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $3.8M on 2022-05-16.

Most recent recorded round closed around 2025-11-13.

Valuation (modeled)modeled

Provath models Enrich Biosystems Inc. at approximately $3.3M (range $1.0M–$6.1M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.72× the median modeled value of Seed Biotechnology companies in 2025–2027 (99 peers) — value vs value, same stage and era. Within the normal band (72% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 14 months.

Last raise 8 mo ago; this sector typically re-raises about every 14 months.

Raising on or ahead of the sector's normal rhythm.

The last round was 1.5× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 52% of Biotechnology peers (4293 compared).

Modeled value ranks above 7% of those peers.

Closest niche peers: Carna Inc., NRX Pharmaceuticals, Inc., Vicora, Inc., MH3D, Inc., Oral Genome Corp..

Peoplefiled

6 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.